Patient adherence strategies - differentiation on the advertising - EU pharma package - Stakeholder Communications - DMPs - Monitoring and ROI - Multi Channel Communication - Managed Care
The non-compliance with prescription drugs is between 30 and 60 percent - of each drug sold is not just about health economic risks but also losses in the billions! But many questions remain regarding patient compliance open: What are the economic consequences of non-compliance? What is possible from the perspective of the industry and how to distinguish information from advertising? What new conditions arising from the EU pharma package? What innovative and successful case studies have proved themselves in practice? Imagine the challenge, increase their market value and offer patients a true added value through targeted communication and long-term compliance and adherence increased.
Congress priorities:
* Discuss current regulatory framework, the definition of advertising, self-regulation in fsa-Code and the future of patient information in accordance with the EU pharma package * Learn how to find out the needs of patients through targeted survey and segmentation, understand the behavior and the information needs of patients and respond with effective programs * Check out successfully implemented compliance programs with multi-channel communication, coaching, action, online portals, telephone service and mail-order pharmacies as an information channel and how intelligent packaging can increase compliance * Exchange ideas in an open discussion with all stakeholders in the health sector about future cooperation around the patient out - cooperation with patient groups or joint programs with health insurance under selective contracts
